ReviewDiscoveries (Craiova, Romania)2021
High mortality co-infections of COVID-19 patients: mucormycosis and other fungal infections.
Review in Discoveries (Craiova, Romania), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
87 citing papers in PubMed, 2 syntheses or guidelines pooled it, 191 citations in OpenAlex.
- Antifungal therapy in the management of fungal secondary infections in COVID-19 patients: A systematic review and meta-analysis.PloS one · 2022Pooled it
- COVID-19-associated mucormycosis: Case report and systematic review.Travel medicine and infectious diseasePooled it
- COVID-19-Associated Fungal Co-Infections: Pathogenesis, Diagnostics, Biomarkers, and Therapeutic Strategies.Journal of clinical medicine · 2026Review
- Active surveillance of cytomegalovirus and pulmonary aspergillosis in critically ill patients with COVID-19: risk assessment of high-dose steroids.BMC infectious diseases · 2026Article
- Review
- Understanding the biology of mucormycosis using contemporary omics tools: a review.Biotechnologia · 2026Review
- COVID-19-Associated Mucormycosis: Identifying Mortality Predictors in a Retrospective Cohort Study.Open forum infectious diseases · 2025Article
- Post-COVID-19 Maxillary Bony Sequestration: A Case Report on Mucormycosis Challenges.Clinical case reports · 2025Article
- Automated Mucormycosis Diagnosis from Paranasal CT Using ResNet50 and ConvNeXt Small.Bioengineering (Basel, Switzerland) · 2025Article
- Global, Regional, and National Burden of Pulmonary Fungal Infections 1990-2021.American journal of respiratory and critical care medicine · 2025Article
- Exploring the therapeutic potential of Thymus vulgaris ethanol extract: a computational screening for antimicrobial compounds against COVID-19 induced mucormycosis.Scientific reports · 2025Article
- Fungal Pulmonary Coinfections in COVID-19: Microbiological Assessment, Inflammatory Profiles, and Clinical Outcomes.Biomedicines · 2025Article
- Fungal positivity seen in tertiary care hospital during COVID-19 pandemic.Access microbiology · 2025Article
- The Value of the Galactomannan Test in Diagnosing COVID-19-Associated Pulmonary Aspergillosis: A Review.Iranian journal of pathology · 2025Review
- Article
- Risk factors for invasive mold infection after COVID-19: case-control study.African health sciences · 2024Article
- Article
- Pulmonary microbial spectrum in late-stage SARS-CoV-2 infection: a case series.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024Article
- Projecting phytochemical bacoside A anti-mucorale agent: An in-silico and in-vitro assessment.Heliyon · 2024Article
- An Experience in Laboratory Diagnosis of Fungal Infections in COVID -19 Patients.International archives of otorhinolaryngology · 2024Article
27 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe COVID-19 disease is associated with an increase in pro-inflammatory markers, such as IL-1, IL-6, and tumor necrosis alpha, less CD4 interferon-gamma expression, and fewer CD4 and CD8 cells, which increase the susceptibility to bacterial and fungal infections. One such opportunistic fungal infection is mucormycosis. Initially, it was debated whether a person taking immunosuppressants, such as corticosteroids, and monoclonal antibodies will be at higher risk for COVID-19 or whether the immunosuppresive state would cause a more severe COVID-19 disease. However, immunosuppressants are currently continued unless the patients are at greater risk of severe COVID-19 infection or are on high-dose corticosteroids therapy. As understood so far, COVID-19 infection may induce significant and persistent lymphopenia, which in turn increases the risk of opportunistic infections. It is also noted that 85% of the COVID-19 patients' laboratory findings showed lymphopenia. This means that patients with severe COVID-19 have markedly lower absolute number of T lymphocytes, CD4+T and CD8+ T cells and, since the lymphocytes play a major role in maintaining the immune homeostasis, the patients with COVID-19 are highly susceptible to fungal co-infections. This report is intended to raise awareness of the importance of early detection and treatment of mucormycosis and other fungal diseases, such as candidiasis, SARS-CoV-2-associated pulmonary aspergillosis, pneumocystis pneumonia and cryptococcal disease, in COVID-19 patients, to reduce the risk of mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.